FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245325155> ?p ?o ?g. }

• W4245325155 abstract "Abstract Background New antimalarial therapeutics are required to counter the threat of increasing drug resistance. Malaria volunteer infection studies (VIS), particularly the induced blood stage malaria (IBSM) model, play a key role in accelerating antimalarial drug development. Supply of the reference 3D7-V2 Plasmodium falciparum malaria cell bank (MCB) is limited. We aimed to develop a new MCB, and compare the safety and infectivity of this MCB with the existing 3D7-V2 MCB, in a VIS. A second bank (3D7-V1) developed in 1995 was also evaluated. Methods We expanded the 3D7-V2 MCB in vitro using a bioreactor to produce a new MCB designated 3D7-MBE-008. This bank and 3D7-V1 were then evaluated using the IBSM model, where healthy participants were intravenously inoculated with blood-stage parasites. Participants were treated with artemether-lumefantrine when parasitaemia or clinical thresholds were reached. Safety, infectivity and parasite growth and clearance were evaluated. Results The in vitro expansion of 3D7-V2 produced 200 vials of the 3D7-MBE-008 MCB, with a parasitaemia of 4.3%. This compares to 0.1% in the existing 3D7-V2 MCB, and <0.01% in the 3D7-V1 MCB. All four participants (two per MCB) developed detectable Plasmodium falciparum infection after inoculation with approximately 2800 parasites. For the 3D7-MBE-008 MCB, the parasite multiplication rate of 48 hours (PMR 48 ) using non-linear mixed effects modelling was 34.6 (95% CI: 18.5 – 64.6), similar to the parental 3D7-V2 line; parasitaemia in both participants exceeded 10,000/mL by day 8. Growth of the 3D7-V1 was slower (PMR 48 of 11.5 [95% CI: 8.5 – 15.6]), with parasitaemia exceeding 10,000 parasites/mL on days 10 and 8.5. Rapid parasite clearance followed artemether-lumefantrine treatment in all four participants, with clearance half-lives of 4.01 and 4.06 (weighted mean 4.04 [95% CI: 3.61 – 4.57]) hours for 3D7-MBE-008 and 4.11 and 4.52 (weighted mean 4.31 [95% CI: 4.16 – 4.47]) hours for 3D7-V1. A total of 59 adverse events occurred; most were of mild severity with three being severe in the 3D7-MBE-008 study. Conclusion The safety, growth and clearance profiles of the expanded 3D7-MBE-008 MCB closely resemble that of its parent, indicating its suitability for future studies. Trial Registration Australian New Zealand Clinical Trials registry numbers:P3487 (3D7-V1): ACTRN12619001085167P3491 (3D7-MBE-008): ACTRN12619001079134" @default.
• W4245325155 created "2022-05-12" @default.
• W4245325155 creator A5007651048 @default.
• W4245325155 creator A5013122674 @default.
• W4245325155 creator A5021130202 @default.
• W4245325155 creator A5023503520 @default.
• W4245325155 creator A5028668027 @default.
• W4245325155 creator A5030264039 @default.
• W4245325155 creator A5050395880 @default.
• W4245325155 creator A5053881011 @default.
• W4245325155 creator A5054757203 @default.
• W4245325155 creator A5069423489 @default.
• W4245325155 creator A5078928068 @default.
• W4245325155 creator A5089122528 @default.
• W4245325155 creator A5090990561 @default.
• W4245325155 date "2021-01-27" @default.
• W4245325155 modified "2023-09-27" @default.
• W4245325155 title "Development and evaluation of a new&nbsp;P. falciparum&nbsp;3D7 blood stage malaria cell bank for use in malaria volunteer infection studies" @default.
• W4245325155 doi "https://doi.org/10.21203/rs.3.rs-90708/v2" @default.
• W4245325155 hasPublicationYear "2021" @default.
• W4245325155 type Work @default.
• W4245325155 citedByCount "0" @default.
• W4245325155 crossrefType "posted-content" @default.
• W4245325155 hasAuthorship W4245325155A5007651048 @default.
• W4245325155 hasAuthorship W4245325155A5013122674 @default.
• W4245325155 hasAuthorship W4245325155A5021130202 @default.
• W4245325155 hasAuthorship W4245325155A5023503520 @default.
• W4245325155 hasAuthorship W4245325155A5028668027 @default.
• W4245325155 hasAuthorship W4245325155A5030264039 @default.
• W4245325155 hasAuthorship W4245325155A5050395880 @default.
• W4245325155 hasAuthorship W4245325155A5053881011 @default.
• W4245325155 hasAuthorship W4245325155A5054757203 @default.
• W4245325155 hasAuthorship W4245325155A5069423489 @default.
• W4245325155 hasAuthorship W4245325155A5078928068 @default.
• W4245325155 hasAuthorship W4245325155A5089122528 @default.
• W4245325155 hasAuthorship W4245325155A5090990561 @default.
• W4245325155 hasBestOaLocation W42453251551 @default.
• W4245325155 hasConcept C106358424 @default.
• W4245325155 hasConcept C203014093 @default.
• W4245325155 hasConcept C2522874641 @default.
• W4245325155 hasConcept C2775867548 @default.
• W4245325155 hasConcept C2776120307 @default.
• W4245325155 hasConcept C2776768635 @default.
• W4245325155 hasConcept C2778048844 @default.
• W4245325155 hasConcept C2778371730 @default.
• W4245325155 hasConcept C2778629330 @default.
• W4245325155 hasConcept C2780780316 @default.
• W4245325155 hasConcept C6557445 @default.
• W4245325155 hasConcept C71924100 @default.
• W4245325155 hasConcept C86803240 @default.
• W4245325155 hasConcept C98274493 @default.
• W4245325155 hasConceptScore W4245325155C106358424 @default.
• W4245325155 hasConceptScore W4245325155C203014093 @default.
• W4245325155 hasConceptScore W4245325155C2522874641 @default.
• W4245325155 hasConceptScore W4245325155C2775867548 @default.
• W4245325155 hasConceptScore W4245325155C2776120307 @default.
• W4245325155 hasConceptScore W4245325155C2776768635 @default.
• W4245325155 hasConceptScore W4245325155C2778048844 @default.
• W4245325155 hasConceptScore W4245325155C2778371730 @default.
• W4245325155 hasConceptScore W4245325155C2778629330 @default.
• W4245325155 hasConceptScore W4245325155C2780780316 @default.
• W4245325155 hasConceptScore W4245325155C6557445 @default.
• W4245325155 hasConceptScore W4245325155C71924100 @default.
• W4245325155 hasConceptScore W4245325155C86803240 @default.
• W4245325155 hasConceptScore W4245325155C98274493 @default.
• W4245325155 hasLocation W42453251551 @default.
• W4245325155 hasLocation W42453251552 @default.
• W4245325155 hasOpenAccess W4245325155 @default.
• W4245325155 hasPrimaryLocation W42453251551 @default.
• W4245325155 hasRelatedWork W2096624589 @default.
• W4245325155 hasRelatedWork W2165065921 @default.
• W4245325155 hasRelatedWork W2801905641 @default.
• W4245325155 hasRelatedWork W2804191972 @default.
• W4245325155 hasRelatedWork W3092770001 @default.
• W4245325155 hasRelatedWork W3127972053 @default.
• W4245325155 hasRelatedWork W3161422354 @default.
• W4245325155 hasRelatedWork W4206094797 @default.
• W4245325155 hasRelatedWork W4214775439 @default.
• W4245325155 hasRelatedWork W4245325155 @default.
• W4245325155 isParatext "false" @default.
• W4245325155 isRetracted "false" @default.
• W4245325155 workType "article" @default.